{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:47:29Z","timestamp":1788410849609,"version":"build-2803163510"},"reference-count":90,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2007,4,18]],"date-time":"2007-04-18T00:00:00Z","timestamp":1176854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2007,7]]},"abstract":"<jats:p><jats:bold>Summary:\u2002<\/jats:bold>Rodent models of chronic epilepsy with spontaneous recurrent seizures likely represent the closest parallel to the human condition. Such models may be best suited for therapy discovery for pharmacoresistant epilepsy and for antiepileptogenic or disease\u2010modifying therapeutics. However, the use of such rodent models for therapy discovery creates problems with regard to maintaining effective drug levels throughout a prolonged testing period. This is particularly due to the fact that rodents such as rats and mice eliminate most drugs much more rapidly than humans. Thus, knowledge about elimination rate of a test drug in a laboratory species is essential for development of a treatment paradigm that allows maintaining adequate drug levels in the system over the period of treatment. Currently, the most popular models of epilepsy with spontaneous seizures are poststatus epilepticus models of temporal lobe epilepsy in rats. Such models are both used for studies on antiepileptogenesis and drug resistance. For validation of these models, current antiepileptic drugs (AEDs) have to be used. In this article, the elimination rates of these AEDs and their effective plasma levels in rats are reviewed as a guide for developing treatment protocols for chronic drug testing. The advantages and disadvantages of several technologies for drug delivery are discussed, and some examples for calculation of adequate treatment protocols are given. As shown in this review, because of the rapid elimination of most AEDs in rats, it is no trivial task to maintain effective steady\u2010state AED levels in the plasma throughout the day over multiple days to ensure that there will be adequate levels in the system for the purpose of the experiment. However, the use of an adequate dosing regimen that is based on elimination rate is an absolute prerequisite when using rat models for discovery of new antiepileptogenic therapies or therapies for pharmacoresistant epilepsy, because otherwise such models may lead to erroneous conclusions about drug efficacy.<\/jats:p>","DOI":"10.1111\/j.1528-1167.2007.01093.x","type":"journal-article","created":{"date-parts":[[2007,4,18]],"date-time":"2007-04-18T16:54:57Z","timestamp":1176915297000},"page":"1245-1258","source":"Crossref","is-referenced-by-count":113,"title":["The Pharmacokinetics of Antiepileptic Drugs in Rats: Consequences for Maintaining Effective Drug Levels during Prolonged Drug Administration in Rat Models of Epilepsy"],"prefix":"10.1111","volume":"48","author":[{"given":"Wolfgang","family":"L\u00f6scher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,4,18]]},"reference":[{"key":"e_1_2_11_2_1","first-page":"1116","article-title":"Felbamate pharmacokinetics in the rat, rabbit, and dog","volume":"19","author":"Adusumalli VE","year":"1991","journal-title":"Drug Metabolism and Disposal: the Biological Fate of Chemicals"},{"issue":"4","key":"e_1_2_11_3_1","first-page":"297","article-title":"Effect of semi\u2010chronic carbamazepine treatment on spontaneous seizures in rats with kainate\u2010induced epilepsy: a drug\u2010in\u2010food method of AED administration","volume":"47","author":"Ali A","year":"2006","journal-title":"Epilepsia"},{"key":"e_1_2_11_4_1","first-page":"297","article-title":"Inhibition of diphenylhydantoin elimination by its major metabolite","volume":"4","author":"Ashley JJ","year":"1972","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"e_1_2_11_5_1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000455547","article-title":"Genetic differences in phenytoin pharmacokinetics: in vivo clearance and in vitro metabolism among inbred strains of mice","volume":"1","author":"Atlas SA","year":"1980","journal-title":"Dev Pharmacol Ther"},{"key":"e_1_2_11_6_1","first-page":"147","volume-title":"New anticonvulsant drugs","author":"Bartoszyk GD","year":"1986"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/0049825042000196749"},{"issue":"8","key":"e_1_2_11_8_1","first-page":"281","article-title":"Testing drugs for antiepileptic efficacy in a rat model of chronic limbic epilepsy","volume":"46","author":"Bertram E","year":"2005","journal-title":"Epilepsia"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.00980.x"},{"key":"e_1_2_11_10_1","first-page":"53","article-title":"Drugs that modify opioid tolerance, physical dependence, and abstinence symptoms: preclinical and clinical studies","volume":"147","author":"Bhargava HN","year":"1995","journal-title":"NIDA Res Monogr"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.32.10.1122"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2006.05.021"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.16904.x"},{"key":"e_1_2_11_14_1","first-page":"565","volume-title":"Antiepileptic drugs","author":"Browne TR","year":"2002"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1980.tb12861.x"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03190614"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1472-8206.2002.00096.x"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2003.09.065"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002809302700215"},{"key":"e_1_2_11_20_1","first-page":"583","article-title":"Disposition of valproic acid in the rat: dose\u2010dependent metabolism, distribution, enterohepatic recirculation and choleretic effect","volume":"211","author":"Dickinson RG","year":"1979","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(98)00104-1"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-60072-2_23"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(94)90631-9"},{"key":"e_1_2_11_24_1","first-page":"125","article-title":"Carbamazepine pharmacokinetics in young, adult and pregnant rats. Relation to pharmacological effects","volume":"220","author":"Farghali H","year":"1976","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"e_1_2_11_25_1","first-page":"97","article-title":"Benzodiazepine withdrawal: behavioural pharmacology and neurochemical changes","volume":"59","author":"File SE","year":"1993","journal-title":"Biochem Soc Symp"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1461-5347(99)00162-5"},{"key":"e_1_2_11_27_1","first-page":"567","article-title":"Study of dose\u2010dependent metabolism of 5,5\u2010diphenyl\u2010hydantoin in the rat using new methodology for isolation and quantitation of metabolites in vivo and in vitro","volume":"178","author":"Gerber N","year":"1971","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008877-199603000-00009"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2002.18101.x"},{"issue":"4","key":"e_1_2_11_30_1","first-page":"306","article-title":"Effects of intraperitoneal and oral carbamazepine on spontaneous seizures in rats with kainate\u2010induced epilepsy","volume":"47","author":"Grabenstatter HL","year":"2006","journal-title":"Epilepsia"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2005.13404.x"},{"key":"e_1_2_11_32_1","first-page":"229","volume-title":"New anticonvulsant drugs","author":"Gram L","year":"1986"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(00)00183-0"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015953715346"},{"key":"e_1_2_11_35_1","first-page":"323","article-title":"Studies upon the sex\u2010difference in rats in tolerance to certain barbiturates and to nicotine","volume":"60","author":"Holck HGO","year":"1937","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(89)90139-1"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1995.tb01613.x"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00497022"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/009841096161960"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498258209038950"},{"key":"e_1_2_11_41_1","first-page":"64","article-title":"Sex\u2010specific cytochrome P450 as a cause of sex\u2010 and species\u2010related differences in drug toxicity","author":"Kato R","year":"1992","journal-title":"Toxicology Letters"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410050512"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(94)00070-D"},{"key":"e_1_2_11_44_1","volume-title":"Antiepileptic drugs","author":"Levy RH","year":"2002"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840100417"},{"key":"e_1_2_11_46_1","first-page":"255","article-title":"Serum protein binding and pharmacokinetics of valproate in man, dog, rat and mouse","volume":"204","author":"L\u00f6scher W","year":"1978","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(86)90449-1"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200216100-00003"},{"key":"e_1_2_11_49_1","first-page":"782","article-title":"Pharmacokinetics of sodium valproate in dog and mouse","volume":"28","author":"L\u00f6scher W","year":"1978","journal-title":"Arzneimittel-Forsch"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(89)90294-X"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1995.tb01637.x"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1728"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(90)90309-T"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(88)90054-X"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(02)00063-3"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2006.03.014"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2006.00607.x"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4886(85)90026-3"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(90)90013-L"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(91)90075-Q"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(91)90062-K"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1995.tb00993.x"},{"key":"e_1_2_11_63_1","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0022-3565(24)37251-9","article-title":"Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy","volume":"284","author":"L\u00f6scher W","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_11_64_1","first-page":"72","volume-title":"Antiepileptic drugs","author":"Mattson RH","year":"2002"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevNeurobiol.v12.i4.40"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1986.tb03572.x"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1258\/002367792780809011"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/0041-008X(85)90081-X"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2510030405"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2510040209"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM.2004.245"},{"key":"e_1_2_11_72_1","first-page":"428","volume-title":"Antiepileptic Drugs","author":"Patsalos PN","year":"2002"},{"key":"e_1_2_11_73_1","first-page":"900","volume-title":"Encyclopedia of controlled drug delivery, version 2","author":"Perkins L","year":"1999"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(88)90150-6"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(98)00074-6"},{"key":"e_1_2_11_76_1","first-page":"441","article-title":"Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys","volume":"23","author":"Radulovic LL","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(92)90624-D"},{"key":"e_1_2_11_78_1","first-page":"216","article-title":"Anticonvulsant efficacy and adverse effects of phenytoin during chronic treatment in amygdala\u2010kindled rats","volume":"266","author":"Rundfeldt C","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(02)00069-4"},{"key":"e_1_2_11_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(88)90007-1"},{"key":"e_1_2_11_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2003.32803.x"},{"key":"e_1_2_11_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(00)00243-8"},{"key":"e_1_2_11_83_1","first-page":"277","volume-title":"New anticonvulsant drugs","author":"Taylor CP","year":"1986"},{"key":"e_1_2_11_84_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161080-00002"},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-69518-6_19"},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2000.00758.x"},{"key":"e_1_2_11_87_1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1600-0773.1971.tb03291.x","article-title":"Pharmacokinetics of diazepam in dogs, mice and humans","volume":"3","author":"Van Der Klejin","year":"1971","journal-title":"Acta Pharmacol Toxicol (Copenh) 29 Suppl"},{"key":"e_1_2_11_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2006.00496.x"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703337"},{"key":"e_1_2_11_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2004.01.007"},{"issue":"8","key":"e_1_2_11_91_1","first-page":"35","article-title":"Pharmacokinetics (PK) and pharmacodynamics (PD) of CI\u20101009 (pregabalin) ans gabapentin in rats with maximal electroshock","volume":"38","author":"Welty D","year":"1997","journal-title":"Epilepsia"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2007.01093.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1167.2007.01093.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T20:50:46Z","timestamp":1736974246000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2007.01093.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,18]]},"references-count":90,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["10.1111\/j.1528-1167.2007.01093.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2007.01093.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4,18]]}}}